Advertisement
Correspondence

Mitochondria: More than Mitochondrial DNA in Cancer

  • Bora Baysal mail

    baysalb@mwri.magee.edu

    Affiliation: University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America

    X
  • Published: March 28, 2006
  • DOI: 10.1371/journal.pmed.0030156

In their PLoS Medicine article, entitled “A critical reassessment of the role of mitochondria in tumorigenesis,” Salas et al. [1] reviewed reports describing identification of mitochondrial DNA (mtDNA) mutations in several tumors. They identified many instances where the purported mutations in tumors corresponded to certain populational haplotypes, suggesting that contamination or sample mix-up could be a better explanation for these mtDNA variations found in tumors. This manuscript has important implications for this research field by questioning the validity of conclusions drawn in several high-profile publications that laid foundations for the role of mtDNA in cancer. While it is essential to investigate the origin of mtDNA variations found in certain tumors, the conclusion in the abstract that “the role of mitochondria in tumorigenesis remains unclarified” is simply incorrect.

The causal link between mitochondrial abnormalities and tumorigenesis was provided by the positional cloning of the hereditary paraganglioma gene at chromosome band 11q23 as the SDHD subunit gene of mitochondrial complex II (succinate dehydrogenase) in the year 2000 [2]. Since then, the role of mitochondria in cancer is further highlighted through identification of over 100 mutations in the SDHB, SDHC, and SDHD subunit genes in hundreds of index cases and families with hereditary and sporadic paragangliomas and pheochromocytomas [3]. Furthermore, fumarase gene mutations in a distinct hereditary tumor syndrome characterized by multiple skin and uterine leiomyomatosis and renal cell cancer—hereditary leiomyomatosis renal cancer (HLRCC)—further strengthened the role of mitochondria in cancer [4].

Although it is clear that Salas et al. question specifically the mutations in mtDNA of tumors, they did not acknowledge the causal link between mitochondria and cancer provided by the discovery of nuclear-encoded mitochondrial gene mutations. This is especially important because, in their unfortunate title and in their conclusion, the authors seem to make a sweeping statement against the role of mitochondria in cancer. It is essential to emphasize to readers that it is the mtDNA, but not mitochondria, which has a questionable role in tumorigenesis.

References

  1. 1. Salas A, Yao YG, Macaulay V, Vega A, Carracedo A, et al. (2005) A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med 2: e296. doi: 10.1371/journal.pmed.0020296.
  2. 2. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287: 848–851.
  3. 3. Bayley JP, Devilee P, Taschner PE (2005) The SDH mutation database: An online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Med Genet 6: 39.
  4. 4. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, et al. (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30: 406–410.